Evidence map›Paper›PMID 31345374›Full record

ArticleOral oncology2019

Intracellular calprotectin (S100A8/A9) controls epithelial differentiation and caspase-mediated cleavage of EGFR in head and neck squamous cell carcinoma.

Prokopios P Argyris, Zachary Slama, Chris Malz, Ioannis G Koutlas, Betty Pakzad, Ketan Patel, Deepak Kademani, Ali Khammanivong, Mark C Herzberg

Open access · greenAbstract read
In one paragraph

Article in Oral oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Regulation of zinc-dependent enzymes by metal carrier proteins.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2022
    Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Prokopios P ArgyrisDepartment of Diagnostic and Biological Sciences, School of Dentistry, University of Minnesota, Minneapolis, MN 55455, USA.
Zachary SlamaDepartment of Diagnostic and Biological Sciences, School of Dentistry, University of Minnesota, Minneapolis, MN 55455, USA.
Chris MalzDepartment of Diagnostic and Biological Sciences, School of Dentistry, University of Minnesota, Minneapolis, MN 55455, USA.
Ioannis G KoutlasDivision of Oral and Maxillofacial Pathology, School of Dentistry, University of Minnesota, Minneapolis, MN 55455, USA.
Betty PakzadAnatomic Clinical Pathology, North Memorial Health Hospital, Minneapolis, MN 55422, USA.
Ketan PatelOral and Maxillofacial Surgery Clinic, North Memorial Health Hospital, Minneapolis, MN 55422, USA.
Deepak KademaniOral and Maxillofacial Surgery Clinic, North Memorial Health Hospital, Minneapolis, MN 55422, USA.
Ali KhammanivongDepartment of Veterinary Clinical Sciences, University of Minnesota, St. Paul, MN, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Mark C HerzbergDepartment of Diagnostic and Biological Sciences, School of Dentistry, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: mcherzb@umn.edu.
University of Minnesota · USNorth Memorial Health Care · USUniversity of Minnesota Medical Center · US

Funding

Minnesota Craniofacial Research Training ProgramR90DE023058 · NIDCR · UNIVERSITY OF MINNESOTA · PI MANSKY, KIM CARPENTER · 2012 to 2022
$1.2M
Augmenting Innate Immunity to Protect the Oral MucosaR01DE021206 · NIDCR · UNIVERSITY OF MINNESOTA · PI HERZBERG, MARK C · 2010 to 2013
$1.2M
A novel, two-armed autotherapy for mucosal infectious diseasesR21DE029337 · NIDCR · UNIVERSITY OF MINNESOTA · PI HERZBERG, MARK C · 2020 to 2021
$461k
NIDCR NIH HHS R01 DE021206NIDCR NIH HHS R21 DE029337NIDCR NIH HHS R90 DE023058
6 · The paper itself

Abstract

objectivesCalprotectin (S100A8/A9) appears to function as a tumor suppressor in head and neck squamous cell carcinoma (HNSCC) and expression in the carcinoma cells and patient survival rates are directly related. We seek to characterize the suppressive role of calprotectin in HNSCC.

aims(1) Investigate changes in S100A8/A9 expression as oral carcinogenesis progresses and (2) determine whether intracellular calprotectin can regulate epidermal growth factor receptor (EGFR), a negative prognostic factor, in HNSCC. MATERIALS AND

methodsUsing immunohistochemistry (IHC), S100A8/A9 was analyzed in HNSCC specimens (N = 46), including well-differentiated (WD, N = 19), moderately-differentiated (MD, N = 14), poorly-differentiated (PD, N = 5) and non-keratinizing/basaloid (NK/BAS, N = 8), and premalignant epithelial dysplasias (PED, N = 16). Similarly, EGFR was analyzed in HNSCCs (N = 21). To determine whether calprotectin and EGFR expression are mechanistically linked, TR146 HNSCC cells that are S100A8/A9-expressing or silenced (shRNA) were compared for EGFR levels and caspase-3/7 activity using western blotting and immunofluorescence microscopy.

resultsIn normal oral mucosal epithelium, S100A8/A9 stained strongly in the cytoplasm and nucleus of suprabasal cells; basal cells were consistently S100A8/A9 negative. In PED and HNSCC, S100A8/A9 expression was lower than in adjacent normal epithelial tissues (NAT) and declined progressively in WD, MD, PD and NK/BAS HNSCCs. S100A8/A9 and EGFR levels appeared inversely related, which was simulated in vitro when S100A8/A9 was silenced in TR146 cells. Silencing S100A8/A9 significantly reduced caspase-3/7 activity, whereas EGFR levels increased.

conclusionsIn HNSCC, S100A8/A9 is directly associated with cellular differentiation and appears to promote caspase-3/7-mediated cleavage of EGFR, which could explain why patients with S100A8/A9-high tumors survive longer.

Indexed as

AdultAgedAged, 80 and overApoptosisCalgranulin ACalgranulin BCaspase 3Caspase 7Cell DifferentiationCell Line, TumorEpithelial CellsErbB ReceptorsFemaleGene Knockdown TechniquesHead and Neck NeoplasmsHumansCalgranulin ACalgranulin BCASP3 protein, humanCASP7 protein, humanCaspase 3Caspase 7EGFR protein, humanErbB ReceptorsLeukocyte L1 Antigen ComplexRNA, Small InterferingS100A8 protein, humanS100A9 protein, humanCalprotectinCaspase-3/7EGFREpithelial differentiationHead and neck squamous cell carcinomaNGFP16+ squamous cell carcinomaPremalignant epithelial dysplasiaS100A8/A9VEGF-AVEGF-C

Identifiers

PMID31345374
PMCPMC6662626
OpenAlexW2948076566

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.